Eli Lilly's has stopped its study evaluating enzastaurin in recurrent glioblastoma, under the recommendation of the External Data Monitoring Committee (DMC). The Phase III study was evaluating enzastaurin for the treatment of an aggressive and recurrent form of brain cancer.
Results of this planned interim analysis suggested that enzastaurin would not meet the primary endpoint of improvement in progression-free survival over an existing chemotherapy. Lilly has thus contacted all study investigators to inform them of the decision.
"Given the independently validated response rate of 22% in a Phase II trial, we plan to thoroughly review the data from this interim analysis and apply the insights learned to the glioblastoma program,” says Richard Gaynor, M.D., vp, cancer research and global oncology platform leader for Eli Lilly. “Based on preclinical and clinical evidence, the company also remains fully committed to the continued development of enzastaurin."